Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's DiseaseStephen Salloway, H. Robert Brashear, Reisa A. Sperling et al.|New England Journal of Medicine|2014Cited by 2k
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M. Clark, Daniel Skovronsky, Robert E. Coleman et al.|The Lancet Neurology|2012Cited by 846
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseStephen Salloway, Michael Grundman, Reisa A. Sperling et al.|Neurology|2009Cited by 739
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 studyOsama Sabri, Marwan N. Sabbagh, John Seibyl et al.|Alzheimer s & Dementia|2015Cited by 605
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysisReisa A. Sperling, Michael Grundman, Stephen Salloway et al.|The Lancet Neurology|2012Cited by 510